Non-steroidal Glucocorticoid Receptor Modulators for Selective Anti-inflammatory Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory and immune-related diseases, such as rheumatoid arthritis and asthma, face limitations due to the systemic side effects of glucocorticoids and the need for compounds that modulate AP-1 and NF-κB activity without inducing metabolic disorders or deficiencies.
Innovation Solution
Development of new non-steroidal compounds that effectively modulate the glucocorticoid receptor, AP-1, and NF-κB activity, specifically designed to treat inflammatory and immune-associated diseases while minimizing side effects and addressing metabolic disorders through targeted transactivation and transrepression mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glucocorticoids are used to treat inflammatory and immune diseases, then anti-inflammatory efficacy is improved, but metabolic side effects worsen
Solution Approach 1:
The invention segments the glucocorticoid receptor's functions by separating transactivation from transrepression. The compounds selectively modulate transrepression (inhibition of NF-κB and AP-1) while minimizing transactivation, thereby achieving anti-inflammatory efficacy without the metabolic side effects associated with traditional glucocorticoids.
Solution Approach 2:
The compounds exhibit local quality by demonstrating selective activity: they preferentially inhibit NF-κB and AP-1 transcription factors in inflammatory pathways while having minimal impact on metabolic pathways. This selective modulation allows targeted therapy that addresses inflammation without causing systemic metabolic disruption.
2Reliability
If NF-κB and AP-1 activity is inhibited to treat inflammatory diseases, then inflammation is reduced, but therapeutic selectivity worsens
Solution Approach 1:
The glucocorticoid receptor serves as an intermediary mechanism. The compounds bind to GR, which then mediates the selective inhibition of NF-κB and AP-1 through transrepression. This intermediary approach allows indirect modulation of inflammatory pathways with high selectivity, avoiding direct inhibition of multiple unrelated targets.
Solution Approach 2:
The invention changes the parameter of selectivity by developing compounds with specific molecular structures ( Formula I and IA) that preferentially engage the transrepression function of GR. This parameter change enables selective targeting of inflammatory pathways while sparing metabolic and other physiological pathways.
3Reliability
If transactivation of glucocorticoid receptor is activated to treat inflammatory diseases, then anti-inflammatory activity is improved, but metabolic disorders worsen
Solution Approach 1:
The invention extracts the beneficial transrepression function from the harmful transactivation function. By designing compounds that selectively engage transrepression (inhibition of NF-κB and AP-1) while minimizing transactivation, the patent separates the anti-inflammatory benefits from the metabolic side effects, effectively taking out the harmful component while retaining the useful one.
Data Source
AI summary
Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I), its enantiomers, diastereomers, or a pharmaceutically acceptable salt, or hydrate, thereof, wherein X is (Ia); or X is (Ib); or X is (Ic); (Id) is heterocycle or heteroaryl; E is —N—, —NR1—, —O—, —S—, —SO2— or —CR2—; F is —N—, —NR1a—, —O—, —S—, —SO2— or —CR2a—; G is N, —NR1b—, —O—, —S—, —SO2— or —CR2b—, provided that the E-F-G containing heterocyclic ring formed does not contain a S—S or S—O bond, and at least one of E, F and G is a heteroatom; J, Ja, M, Ma, Q, Rx, Ry, R1, R1a, R1b, R2, R2a, R2b, and R3 to R21, Z, Za, Zb, and Zc are as defined above.